Stock analysts at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a report issued on Wednesday. The brokerage set a “sell” rating on the stock.
Bio-Path Trading Up 7.3 %
BPTH stock opened at $0.72 on Wednesday. Bio-Path has a 1 year low of $0.59 and a 1 year high of $12.00. The stock’s fifty day moving average is $0.89 and its two-hundred day moving average is $1.32.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent SEC filing. 5.74% of the stock is currently owned by institutional investors and hedge funds.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Read More
- Five stocks we like better than Bio-Path
- How to Find Undervalued Stocks
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
- Why Invest in High-Yield Dividend Stocks?
- Salesforce’s Clear Path to $400 and Beyond
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
